Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients

被引：0
|
作者：
Rifa, Juli [1 ]
Del Alba, A. Gonzalez [1 ]
Perello, A. [1 ]
Alarcon, J. [1 ]
Avella, A. [1 ]
机构：
[1] Hosp Son Dureta, Palma De Mallorca, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [21] Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC):: An interim safety analysis of the GEICAM 9805 study.
    Martin, M
    Lluch, A
    Seguí, MA
    Antón, A
    Ruiz, A
    Ramos, M
    Rodríguez-Lescure, A
    Adrover, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 32S - 32S
  • [22] Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis
    Wolowacz, Sorrel E.
    Cameron, David A.
    Tate, Helen C.
    Bagust, Adrian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 925 - 933
  • [23] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    Hatam, N.
    Ahmadloo, N.
    Kiadaliri, A. Ahmad
    Bastani, P.
    Askarian, M.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 284 (01) : 215 - 220
  • [24] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    N. Hatam
    N. Ahmadloo
    A. Ahmad Kia Daliri
    P. Bastani
    M. Askarian
    Archives of Gynecology and Obstetrics, 2011, 284 : 215 - 220
  • [25] Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
    Puhalla, Shannon
    Mrozek, Ewa
    Young, Donn
    Ottman, Susan
    McVey, Anne
    Kendra, Kari
    Merriman, Nancy J.
    Knapp, Mark
    Patel, Taral
    Thompson, Mark E.
    Maher, James F.
    Moore, Timothy D.
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1691 - 1697
  • [26] Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis
    Wolowacz, S. E.
    Seal, B. S.
    Tangirala, M.
    CANCER RESEARCH, 2009, 69 (24) : 622S - 623S
  • [27] Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer
    Mittmann, N.
    Verma, S.
    Koo, M.
    Alloul, K.
    Trudeau, M.
    CURRENT ONCOLOGY, 2010, 17 (01) : 7 - 16
  • [28] Adjuvant Chemotherapy with TAC (Docetaxel, Doxorubicin, and Cyclophosphamide) in Patients with Breast Cancer - Incidence of Neutropenic Fever Outside Clinical Trials
    Passos-Coelho, Jose L.
    Esteves, Susana
    Vieira, Paula A.
    Isidoro, Miguel
    Ribeiro, Manuel
    Oliveira, Joao
    Moreira, Antonio R.
    BREAST JOURNAL, 2011, 17 (05): : 539 - 541
  • [29] ADJUVANT RANDOMIZED TRIALS OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN CYCLOPHOSPHAMIDE TAMOXIFEN AND CMF CHEMOTHERAPY VERSUS TAMOXIFEN IN WOMEN WITH NODE-POSITIVE BREAST-CANCER
    KAUFMANN, M
    JONAT, W
    ABEL, U
    HILFRICH, J
    CAFFIER, H
    KREIENBERG, R
    TRAMS, G
    BRUNNERT, K
    SCHERMANN, J
    KLEINE, W
    MAHLKE, M
    NEISES, M
    STOSIEK, U
    STIGLMAYER, R
    SEEGER, F
    LANGNICKEL, D
    NAGEL, G
    GAMPE, M
    MAASS, H
    KUBLI, F
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 454 - 460
  • [30] Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
    Mackey, John R.
    Martin, Miguel
    Pienkowski, Tadeusz
    Rolski, Janusz
    Guastalla, Jean-Paul
    Sami, Amer
    Glaspy, John
    Juhos, Eva
    Wardley, Andrew
    Fornander, Tommy
    Hainsworth, John
    Coleman, Robert
    Modiano, Manuel R.
    Vinholes, Jeferson
    Pinter, Tamas
    Rodriguez-Lescure, Alvaro
    Colwell, Bruce
    Whitlock, Pierre
    Provencher, Louise
    Laing, Kara
    Walde, David
    Price, Chris
    Hugh, Judith C.
    Childs, Barrett H.
    Bassi, Kimberly
    Lindsay, Mary-Ann
    Wilson, Veronique
    Rupin, Matthieu
    Houe, Vincent
    Vogel, Charles
    LANCET ONCOLOGY, 2013, 14 (01): : 72 - 80
12345